F-star
Manufacturing · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
B920 Babraham Research Campus, Cambridge...Phone Number
+44 1223497400Website
www.f-star.comRevenue
$21.2 MillionStock Symbol
FSTXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About F-star
F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a transformation in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company's goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb) format, F-star's mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.Explore more
F-star Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is F-star your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if F-star has recently received funding, and reach out quickly before it becomes old news!
Click to see if F-star had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at F-star
F-star, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on F-star recently announced quarterly report
Check out if F-star is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when F-star launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once F-star has new funding data
Recommended Actions
Reach out to Masked Content who joined F-star as Masked Content
Find 2 more new buyers
Compare Similar Companies to F-star
Compare insights from companies similar to F-star, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
F-star is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
F-star is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about F-star.
F-star financials insights
Gather financial insights about F-star, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Angel/Seed
$2M
2011
Unspecified
$20.3M
2013
Series A
$12.9M
F-star Tech Stack
A closer look at the technologies used by F-star
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Open Position
Open Position
Left Company
Executive Move
F-star News & Media
F-star charts new path, splitting from invoX after 2023's $161M acquisition - Fierce Biotech
After a drawn-out acquisition that closed in 2023, U.K. biotech F-star Therapeutics is charting its own path as a private, independent company. | After a drawn-out acquisition that closed in 2023, U.K. biotech F-star Therapeutics is charting its own path as a private, independent company.F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender Offer Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender OfferWhile institutions own 48% of F-star Therapeutics, Inc. (NASDAQ:FSTX), retail investors are its largest shareholders with 49% ownership
Key Insights F-star Therapeutics' significant retail investors ownership suggests that the key decisions are influenced...F-star's Delayed Acquisition Presents A Risky Opportunity - Seeking Alpha
FSTX seems undervalued, even at the $7.12 takeover bid. CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns. Read more here.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding F-star
Sign Up For FreeTo access detailed company insights
F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a transformation in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company's goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetraval... Read More
